Literature DB >> 8244258

The pathology of hepatitis C as a function of mode of transmission: blood transfusion vs. intravenous drug use.

S C Gordon1, R S Elloway, J C Long, C F Dmuchowski.   

Abstract

We reviewed the clinical records of 140 consecutively evaluated patients with chronic hepatitis C infection. One hundred twenty-four patients (89%) contracted infection through blood transfusion or intravenous drug use. The liver biopsy specimens of 83 patients (43 blood transfusion cases and 40 intravenous drug abuse cases) were examined without knowledge of the mode of disease transmission. The mean histological activity index score was significantly higher in the blood transfusion group (10.2 +/- 4.2) than in the intravenous drug use group (6.9 +/- 4.5) (p = 0.001). The transfusion group had more periportal bridging necrosis (p = 0.0015) and fibrosis (p = 0.0016) than did the intravenous drug use group, whereas significant differences between lobular degeneration and portal inflammation were not achieved across the two groups. The distribution of final biopsy interpretations also differed significantly between the two groups (p < 0.001), with chronic active hepatitis more frequent in the transfusion group. Moreover, lymphoid aggregates and bile duct damage were more common in patients with chronic hepatitis due to blood transfusion. Multivariate analysis showed that the mode of viral transmission was the most powerful predictor of histological activity index score when tested against patient gender, duration of disease or age at biopsy. One year after completion of this study, 9 of 70 transfused patients and 1 of 54 intravenous drug users had died of liver disease or are awaiting liver transplantation at this writing (p = 0.03). We conclude that transfusion-acquired hepatitis C is associated with more aggressive histological inflammatory activity than hepatitis resulting from intravenous drug use.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8244258

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  23 in total

1.  Hepatitis C virus serotypes and sources of infection in patients with HCV-related chronic liver disease from one geographical area in southeast Italy.

Authors:  P Dentico; N Curatolo; R Sacco; M De Luca; A Volpe; C Ranieri; C Genchi; L Petracca; R Buongiorno
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

2.  Clinical guidelines on the management of hepatitis C.

Authors:  J C Booth; J O'Grady; J Neuberger
Journal:  Gut       Date:  2001-07       Impact factor: 23.059

3.  Predictors and noninvasive identification of severe liver fibrosis in patients with chronic hepatitis C.

Authors:  Mohamed A Metwally; Claudia O Zein; Nizar N Zein
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

4.  Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

Authors:  A Sánchez-Quijano; J Andreu; F Gavilán; F Luque; M A Abad; B Soto; J Muñoz; J M Aznar; M Leal; E Lissen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

5.  Screening asymptomatic people at high risk for hepatitis C. The case against.

Authors:  M C Allison; P R Mills
Journal:  BMJ       Date:  1996-05-25

6.  Clinical sequelae of hepatitis C acquired from injection drug use.

Authors:  M J Tong; N S el-Farra
Journal:  West J Med       Date:  1996-05

7.  Hepatitis C virus--a pathogen for all people.

Authors:  L Dove; T L Wright
Journal:  West J Med       Date:  1996-06

8.  Human immunodeficiency virus-related microbial translocation and progression of hepatitis C.

Authors:  Ashwin Balagopal; Frances H Philp; Jacquie Astemborski; Timothy M Block; Anand Mehta; Ronald Long; Gregory D Kirk; Shruti H Mehta; Andrea L Cox; David L Thomas; Stuart C Ray
Journal:  Gastroenterology       Date:  2008-03-29       Impact factor: 22.682

9.  Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors.

Authors:  Anne M Guiltinan; Zhanna Kaidarova; Brian Custer; Jennie Orland; Angela Strollo; Sherri Cyrus; Michael P Busch; Edward L Murphy
Journal:  Am J Epidemiol       Date:  2008-01-17       Impact factor: 4.897

Review 10.  Fat, diabetes, and liver injury in chronic hepatitis C.

Authors:  Vlad Ratziu; Jean-Baptiste Trabut; Thierry Poynard
Journal:  Curr Gastroenterol Rep       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.